News

Editas Medicine Announces Second Quarter 2024 Results and Business Updates

On track to present additional clinical data from the RUBY trial and the EdiTHAL trial by year-end In vivo preclinical…

1 year ago

EyePoint Pharmaceuticals Reports Second Quarter 2024 Financial Results and Highlights Recent Corporate Developments

– Phase 3 LUGANO pivotal non-inferiority clinical trial of DURAVYU™ in wet AMD on track for first patient dosing in…

1 year ago

Aclaris Therapeutics Reports Second Quarter 2024 Financial Results and Provides a Corporate Update

-Initiated Phase 2a Study Activities for ATI-2138 in Atopic Dermatitis--Strengthened Balance Sheet Through Sale of Future OLUMIANT® Royalties for Proceeds…

1 year ago

Kymera Therapeutics Announces Second Quarter 2024 Financial Results and Provides a Business Update

Sanofi plans to expand KT-474/SAR444656 (IRAK4) Phase 2 clinical trials in HS and AD to accelerate overall development timelines following…

1 year ago

Applied Therapeutics Reports Second Quarter 2024 Financial Results

NDA and MAA for govorestat for treatment of Classic Galactosemia under FDA Priority Review and EMA review; PDUFA target action…

1 year ago

Larimar Therapeutics Reports Second Quarter 2024 Operating and Financial Results

Open label extension (OLE) study is progressing with all 7 sites activated; interim data planned for Q4 2024Selected by Food…

1 year ago

SprintRay Announces The Midas Restoration Tour: Advancing Restorative Dentistry with AI-Powered Digital Workflow and 3D Printing

LOS ANGELES, Aug. 7, 2024 /PRNewswire/ -- SprintRay is excited to announce The Midas Restoration Tour, an event series to…

1 year ago

LICORbio and Bioz Collaborate to Elevate Scientific Insights With Advanced Publication Data Integration

PALO ALTO, CA / ACCESSWIRE / August 7, 2024 / Bioz, Inc., a pioneer in AI-driven research solutions, is excited…

1 year ago

New Results from AlzeCure’s Pain Project TrkA-NAM Presented at the Pain Conference IASP 2024

STOCKHOLM, SE / ACCESSWIRE / August 07, 2024 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) AlzeCure Pharma AB (publ) (FN STO: ALZCUR), a…

1 year ago

Scryb Announces Private Placement of Units

Toronto, Ontario--(Newsfile Corp. - August 6, 2024) - Scryb Inc. (CSE: SCYB) (OTCQB: SCYRF) (FSE: EIY) ("Scryb'' or the "Company"),…

1 year ago